Legal & General Group’s DICE Therapeutics, Inc. Common Stock DICE Stock Holding History

Legal & General Group’s Portfolio DICE Stock Details DICE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-29,738	Closed	-$1.38M	–	3441
2023 Q2	$1.38M	Buy	29,738 +13,963	+89%	+$483K	﹤0.01%	2084
2023 Q1	$452K	Buy	15,775 +1,437	+10%	+$42.6K	﹤0.01%	2342
2022 Q4	$447K	Buy	14,338 +9,256	+182%	+$302K	﹤0.01%	2367
2022 Q3	$104K	Buy	5,082 +318	+7%	+$5.79K	﹤0.01%	2813
2022 Q2	$74K	Buy	4,764 +3,459	+265%	+$59.5K	﹤0.01%	2924
2022 Q1	$25K	Buy	1,305 +15	+1%	+$268	﹤0.01%	3179
2021 Q4	$33K	Buy	+1,290	New	+$37.8K	﹤0.01%	3126

Legal & General Group's DICE Position: Q3 2023 in Review

Legal & General Group sold out of DICE Therapeutics, Inc. Common Stock (DICE) in Q3 2023, closing a stake of 29,738 shares — an estimated $1.38M sold.

Legal & General Group first reported a position in DICE in Q4 2021 and held it in 7 quarters. The position peaked at $1.38M in Q2 2023. 0 funds tracked by Wall St. Rank hold DICE as of Q3 2023.

Legal & General Group reported no remaining DICE Therapeutics, Inc. Common Stock position as of Q3 2023 after selling out during the quarter.
Legal & General Group sold 29,738 DICE Therapeutics, Inc. Common Stock shares in Q3 2023, an estimated $1.38M.
Legal & General Group first reported a position in DICE Therapeutics, Inc. Common Stock in Q4 2021 and held it in 7 quarters.
Legal & General Group's DICE Therapeutics, Inc. Common Stock position peaked at $1.38M in Q2 2023.
0 funds tracked by Wall St. Rank held DICE Therapeutics, Inc. Common Stock as of Q3 2023.

Based on Legal & General Group's 13F filing for Q3 2023, filed 14 Nov 2023.